Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,056 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC; KIDCARE Multicenter Study Group; Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S. Roberts SC, et al. Among authors: yeh s. Contemp Clin Trials. 2019 Apr;79:98-103. doi: 10.1016/j.cct.2019.02.008. Epub 2019 Mar 3. Contemp Clin Trials. 2019. PMID: 30840903 Free article.
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S; KIDCARE Multicenter Study Group. Burns JC, et al. Lancet Child Adolesc Health. 2021 Dec;5(12):852-861. doi: 10.1016/S2352-4642(21)00270-4. Epub 2021 Oct 27. Lancet Child Adolesc Health. 2021. PMID: 34715057 Free article. Clinical Trial.
Epidemiological and Clinical Features of Kawasaki Disease During the COVID-19 Pandemic in the United States.
Burney JA, Roberts SC, DeHaan LL, Shimizu C, Bainto EV, Newburger JW, Dominguez S, Jone PN, Jaggi P, Szmuszkovicz JR, Rowley AH, Samuy N, Scalici P, Tremoulet AH, Cayan DR, Burns JC; KIDCARE Study Investigators. Burney JA, et al. JAMA Netw Open. 2022 Jun 1;5(6):e2217436. doi: 10.1001/jamanetworkopen.2022.17436. JAMA Netw Open. 2022. PMID: 35713905 Free PMC article.
Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial.
Parsons MW, Yogendrakumar V, Churilov L, Garcia-Esperon C, Campbell BCV, Russell ML, Sharma G, Chen C, Lin L, Chew BL, Ng FC, Deepak A, Choi PMC, Kleinig TJ, Cordato DJ, Wu TY, Fink JN, Ma H, Phan TG, Markus HS, Molina CA, Tsai CH, Lee JT, Jeng JS, Strbian D, Meretoja A, Arenillas JF, Buck BH, Devlin MJ, Brown H, Butcher KS, O'Brien B, Sabet A, Wijeratne T, Bivard A, Grimley RS, Agarwal S, Munshi SK, Donnan GA, Davis SM, Miteff F, Spratt NJ, Levi CR; TASTE investigators. Parsons MW, et al. Lancet Neurol. 2024 Jun 13:S1474-4422(24)00206-0. doi: 10.1016/S1474-4422(24)00206-0. Online ahead of print. Lancet Neurol. 2024. PMID: 38880118
DUSP22 inhibits lung tumorigenesis by suppression of EGFR/c-Met signaling.
Lin HH, Chang CW, Liao YT, Yeh SD, Lin HP, Ho HM, Cheung CH, Juan HF, Chen YR, Su YW, Chen LM, Tan TH, Lin WJ. Lin HH, et al. Among authors: yeh sd. Cell Death Discov. 2024 Jun 14;10(1):285. doi: 10.1038/s41420-024-02038-8. Cell Death Discov. 2024. PMID: 38877005 Free PMC article.
3,056 results